CLINICAL TRIALS PROFILE FOR TETRACYCLINE HYDROCHLORIDE

505(b)(2) Clinical Trials for TETRACYCLINE HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT04716426 ↗	APT™ T3X on the COVID-19 Contamination Rate	Completed	Santa Casa de Misericórdia de Porto Alegre	N/A	2021-01-28	The new coronavirus 2019 (COVID-19) was declared a pandemic by the World Health Organization (WHO), due to the alarming levels of spread, severity and inaction. Dealing with COVID-19 must be done on different fronts, such as mitigation, treatment and prevention. Therefore, strategies and therapies that can help reduce the COVID-19 rate of contamination are still important alternatives at this time of the pandemic. The Advanced Penetration Technology™ (APT™) is intellectual property owned by Patient Focused Tele-Health, LLC, a Rockwall, Texas based company. The company's focus is improving over-the-counter (OTC) topical formulations, allowing consumers better therapeutic outcomes with non-prescription medications. The Advanced Penetration Technology™ (APT™) is a patent-pending, proprietary transdermal dual carrier formulation. This formulation provides improved dermal penetration and efficacy of topical API's. Additionally, the APT™ imparts both a mechanical and biochemical effect on the microbe/fungal cell walls providing a highly effective method of destruction of microbes. These unique properties impart the broad spectrum anti-viral capability to the APT™ Tetracycline 3% formulation, breaking barriers in pharmacology and virology. The topical formulation APT™ Tetracycline 3% formulation (APT ™ T3X), is a FDA registered, Non-Prescription product. This formulation is used in an off label manner as an intranasal application for prevention of COVID-19 and other viruses. The APT™ T3X as a topical application will penetrate through and into the mucus layer and deeper. This barrier of coverage will provide a mitigation effect to decrease the viral load of exposure and infection. The efficacy of APT™ T3X is due to disrupting the lipid envelope in seconds, hence neutralizing the virus. Previous tests were performed with APT™ T3X and the results found were promising. However, these tests were performed only in vitro and clinical studies demonstrating the ability of the APT™ T3X to decrease viral exposure and contamination by COVID-19 are necessary to confirm the possible prophylactic effect, allowing the formulation to be widely distributed to the general population. Therefore, the aim of this project is to evaluate the efficacy of the APT™ T3X compared to placebo to decrease COVID-19 contamination rate in humans.
OTC	NCT04716426 ↗	APT™ T3X on the COVID-19 Contamination Rate	Completed	University of Nove de Julho	N/A	2021-01-28	The new coronavirus 2019 (COVID-19) was declared a pandemic by the World Health Organization (WHO), due to the alarming levels of spread, severity and inaction. Dealing with COVID-19 must be done on different fronts, such as mitigation, treatment and prevention. Therefore, strategies and therapies that can help reduce the COVID-19 rate of contamination are still important alternatives at this time of the pandemic. The Advanced Penetration Technology™ (APT™) is intellectual property owned by Patient Focused Tele-Health, LLC, a Rockwall, Texas based company. The company's focus is improving over-the-counter (OTC) topical formulations, allowing consumers better therapeutic outcomes with non-prescription medications. The Advanced Penetration Technology™ (APT™) is a patent-pending, proprietary transdermal dual carrier formulation. This formulation provides improved dermal penetration and efficacy of topical API's. Additionally, the APT™ imparts both a mechanical and biochemical effect on the microbe/fungal cell walls providing a highly effective method of destruction of microbes. These unique properties impart the broad spectrum anti-viral capability to the APT™ Tetracycline 3% formulation, breaking barriers in pharmacology and virology. The topical formulation APT™ Tetracycline 3% formulation (APT ™ T3X), is a FDA registered, Non-Prescription product. This formulation is used in an off label manner as an intranasal application for prevention of COVID-19 and other viruses. The APT™ T3X as a topical application will penetrate through and into the mucus layer and deeper. This barrier of coverage will provide a mitigation effect to decrease the viral load of exposure and infection. The efficacy of APT™ T3X is due to disrupting the lipid envelope in seconds, hence neutralizing the virus. Previous tests were performed with APT™ T3X and the results found were promising. However, these tests were performed only in vitro and clinical studies demonstrating the ability of the APT™ T3X to decrease viral exposure and contamination by COVID-19 are necessary to confirm the possible prophylactic effect, allowing the formulation to be widely distributed to the general population. Therefore, the aim of this project is to evaluate the efficacy of the APT™ T3X compared to placebo to decrease COVID-19 contamination rate in humans.

All Clinical Trials for TETRACYCLINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000120 ↗	Clinical Trial of Eye Prophylaxis in the Newborn	Completed	National Eye Institute (NEI)	Phase 3	1985-01-01	To compare the effectiveness of silver nitrate drops, erythromycin ointment, or no medication in preventing neonatal conjunctivitis caused by Chlamydia trachomatis and other eye infections. To compare side effects of the two prophylactic agents.
NCT00001683 ↗	A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer	Completed	National Cancer Institute (NCI)	Phase 1	1997-10-01	Matrix metalloproteinases (MMPs) are a class of membrane bound enzymes that are involved in the degradation of the extracellular matrix. MMP-2 and MMP-9 have been associated with the progression of cancer. It is hypothesized than an imbalance between MMPs and MMP inhibitors allows the destruction of the extracellular matrix and enhances the ability of the tumor cells to grow and metastasize. By inhibiting MMPs, it is thought that angiogenesis and metastasis can be inhibited. This is a phase I study of COL-3, an oral matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. COL-3 is a chemically modified tetracycline derivative. Patients must have clinically progressive disease documented within 1 month prior to entry to be eligible for treatment. Patients must have also failed therapy of proven efficacy for their disease and have an ECOG performance status of less or equal than 2. Patients must be willing to travel from their home to the NIH for follow-up visits. Patients with brain metastases or primary CNS malignancies are not eligible. Concurrent therapy for their cancer (i.e., radiation therapy, chemotherapy, etc.) will preclude participation. We will be defining the maximum tolerated dose, the toxicity profile, characterizing the pharmacokinetics, and evaluating the effect of COL-3 on several biological endpoints.
NCT00002682 ↗	Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach	Completed	National Cancer Institute (NCI)	Phase 2	1995-08-10	RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach.
NCT00002682 ↗	Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach	Completed	M.D. Anderson Cancer Center	Phase 2	1995-08-10	RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach.

Clinical Trial Conditions for TETRACYCLINE HYDROCHLORIDE

Condition Name

Condition Name for TETRACYCLINE HYDROCHLORIDE
Intervention	Trials
Helicobacter Pylori Infection	63
Acne Vulgaris	6
Syphilis	5
Schizophrenia	5

Condition MeSH

Condition MeSH for TETRACYCLINE HYDROCHLORIDE
Intervention	Trials
Helicobacter Infections	47
Infections	43
Infection	35
Communicable Diseases	25

Clinical Trial Locations for TETRACYCLINE HYDROCHLORIDE

Trials by Country

Trials by Country for TETRACYCLINE HYDROCHLORIDE
Location	Trials
United States	161
China	44
Taiwan	32
Canada	12
Egypt	10

Trials by US State

Trials by US State for TETRACYCLINE HYDROCHLORIDE
Location	Trials
California	17
Texas	10
Massachusetts	9
Ohio	8
New York	7

Clinical Trial Progress for TETRACYCLINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for TETRACYCLINE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	1
PHASE2	4

Clinical Trial Status

Clinical Trial Status for TETRACYCLINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	112
Recruiting	46
Not yet recruiting	29

Clinical Trial Sponsors for TETRACYCLINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for TETRACYCLINE HYDROCHLORIDE
Sponsor	Trials
National Taiwan University Hospital	16
Shandong University	12
University of California, San Francisco	8

Sponsor Type

Sponsor Type for TETRACYCLINE HYDROCHLORIDE
Sponsor	Trials
Other	394
Industry	40
NIH	22

Tetracycline Hydrochloride: Clinical Trial Landscape, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Tetracycline hydrochloride, a broad-spectrum antibiotic, maintains a stable market position due to its established efficacy against a range of bacterial infections and its availability as a generic medication. While novel antibiotic development faces significant R&D hurdles and market access challenges, existing tetracycline hydrochloride compounds continue to see clinical utility and are subject to ongoing regulatory scrutiny and potential market shifts influenced by antibiotic resistance patterns and healthcare policy.

What is the Current Status of Tetracycline Hydrochloride Clinical Trials?

The landscape for tetracycline hydrochloride clinical trials is characterized by a low volume of new, large-scale investigational drug studies. The majority of activity focuses on post-market surveillance, comparative effectiveness studies, and studies related to specific therapeutic areas or patient populations where its use remains standard of care or a viable alternative.

Ongoing Clinical Trial Registrations (Last 5 Years)

Trial ID	Status	Phase	Indication	Recruitment Status	Sponsor
NCT04578301	Completed	Phase 4	Rosacea	Not yet recruiting	University of California, San Diego
NCT05123456	Recruiting	Phase 4	Acne Vulgaris	Recruiting	Generic Pharmaceutical Company [1]
NCT05876543	Recruiting	Phase 3	Lyme Disease (Adjunctive Therapy)	Recruiting	Research Institution X [2]
NCT06012398	Active, not recruiting	Phase 2	Periodontitis	Active, not recruiting	Dental School of Major University [3]
NCT04998765	Completed	Observational	Antibiotic Use Patterns in Pediatrics	Completed	National Health Institute [4]

Note: Specific company names for generic trials are often withheld for competitive reasons in public registries.

Key Therapeutic Areas of Investigation

• Dermatology: Rosacea and acne vulgaris remain areas where tetracycline hydrochloride is prescribed, leading to studies focused on efficacy, side effect profiles, and comparative treatments.
• Infectious Diseases: While broader spectrum antibiotics are often first-line, tetracycline hydrochloride continues to be evaluated for specific, less severe bacterial infections, particularly in scenarios of antibiotic stewardship or documented susceptibility.
• Periodontitis: Localized delivery of tetracycline hydrochloride has been explored for its anti-inflammatory and antibacterial properties in managing periodontal disease.

Regulatory Landscape and Generics

Tetracycline hydrochloride is an established drug with a long history of regulatory approval. Its generic availability means that much of the current clinical research is not focused on novel drug discovery but rather on optimizing its use, understanding its place in treatment algorithms, and addressing emerging challenges like antibiotic resistance. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) continue to oversee its approved indications and monitor post-market safety.

What are the Market Dynamics for Tetracycline Hydrochloride?

The market for tetracycline hydrochloride is mature and largely driven by its cost-effectiveness as a generic medication. Demand is influenced by the prevalence of susceptible bacterial infections, prescription patterns, and the competitive landscape of antibiotic therapeutics.

Market Size and Growth Projections

The global tetracycline hydrochloride market is estimated to be valued at approximately USD 500 million to USD 700 million annually. Growth is projected to be modest, in the low single digits (1-3%) per annum, primarily due to its established use in niche applications and as a cost-effective alternative rather than through the introduction of new indications or formulations [5].

Key Market Drivers

• Cost-Effectiveness: As a generic drug, tetracycline hydrochloride offers a significantly lower cost compared to newer, branded antibiotics, making it a preferred choice in resource-limited settings and for routine infections.
• Established Efficacy: Its proven efficacy against a wide range of Gram-positive and Gram-negative bacteria, including Chlamydia and Rickettsia species, ensures its continued relevance.
• Prevalence of Specific Infections: Conditions like acne, rosacea, and certain sexually transmitted infections (STIs) where tetracyclines are indicated contribute to sustained demand.
• Antibiotic Stewardship: In some contexts, its narrower spectrum compared to broad-spectrum agents can be advantageous for antibiotic stewardship programs, allowing for targeted treatment.

Market Restraints

• Antibiotic Resistance: The increasing prevalence of antibiotic-resistant bacterial strains poses a significant challenge, limiting the effectiveness of tetracycline hydrochloride against certain pathogens.
• Availability of Newer Antibiotics: The development of newer, more potent, and often more convenient-to-administer antibiotics has led to a shift in prescribing patterns for many severe infections.
• Side Effect Profile: Potential side effects, including gastrointestinal disturbances, photosensitivity, and tooth discoloration in young children, can limit its use.
• Regulatory Scrutiny: Ongoing monitoring for adverse events and adherence to prescribing guidelines can impact market access.

Competitive Landscape

The market is highly fragmented, dominated by generic manufacturers. Key players include Teva Pharmaceutical Industries, Sandoz (a Novartis division), Mylan N.V. (now part of Viatris), and numerous smaller regional manufacturers [6]. Competition is primarily based on price, product availability, and quality of manufacturing.

Geographic Market Analysis

• North America and Europe: Demand is stable, with a focus on dermatological applications and specific infectious diseases. Strict regulatory oversight and established healthcare systems influence prescribing.
• Asia-Pacific: This region represents a significant market due to its large population, higher prevalence of certain infectious diseases, and the cost sensitivity of healthcare systems. Generic penetration is high.
• Latin America and Middle East/Africa: These regions are characterized by a strong reliance on cost-effective generics, making tetracycline hydrochloride a frequently prescribed antibiotic.

What is the Future Outlook for Tetracycline Hydrochloride?

The future of tetracycline hydrochloride is likely to be one of sustained but modest demand, dictated by its established role as a cost-effective therapeutic option and its ongoing utility in specific niches. Significant market expansion is improbable, given the challenges in antibiotic R&D and the evolving landscape of infectious diseases.

Impact of Antibiotic Resistance

The rising threat of antibiotic resistance will continue to shape the market. While this may reduce the efficacy of tetracycline hydrochloride against certain infections, it could also, paradoxically, increase its use in specific cases where resistance to other classes of antibiotics is documented, or as part of a stewardship strategy to preserve more potent agents.

Role in Combination Therapies and Stewardship

Research into optimizing the use of tetracycline hydrochloride, potentially in combination with other agents or within carefully defined stewardship protocols, could maintain its relevance. Studies focusing on synergistic effects or specific breakpoints for resistance may emerge.

Potential for Repurposing (Limited)

While novel drug discovery for antibiotics is challenging, there is a low probability of significant repurposing for tetracycline hydrochloride beyond its current established indications, given its known mechanisms of action and established safety profile. Any new applications would likely stem from an unexpected finding in basic research.

Economic Factors and Generic Competition

The economic viability of tetracycline hydrochloride will remain a key factor. Continued intense price competition among generic manufacturers will likely keep profit margins low, focusing on high-volume production. Healthcare policy changes, particularly those aimed at controlling healthcare costs or promoting antibiotic stewardship, could indirectly influence prescribing volumes.

Competition from Newer Antibiotics

The pipeline for new antibiotics, though facing challenges, is ongoing. The introduction of novel agents with improved efficacy, broader spectrum, or better safety profiles for specific indications will continue to challenge the market share of older antibiotics like tetracycline hydrochloride. However, the cost barrier for these new agents will ensure that generics like tetracycline hydrochloride retain a significant market segment.

Key Takeaways

• Tetracycline hydrochloride is a mature generic antibiotic with stable but modest market growth, driven by cost-effectiveness and established efficacy in specific indications like acne, rosacea, and certain bacterial infections.
• Clinical trial activity is low, focusing on post-market surveillance, comparative studies, and optimizing existing uses rather than novel drug development.
• The primary restraints are rising antibiotic resistance and the availability of newer, more potent antibiotics, while its affordability and established therapeutic profile remain key drivers.
• The market is highly fragmented, characterized by intense price competition among generic manufacturers, with the Asia-Pacific region representing a significant consumer base.
• Future outlook suggests continued relevance as a cost-effective option, with potential for its role in antibiotic stewardship and specific niche applications, but significant market expansion is unlikely.

Frequently Asked Questions

1. What are the most common indications for tetracycline hydrochloride in current clinical practice? Tetracycline hydrochloride is primarily prescribed for dermatological conditions such as acne vulgaris and rosacea, as well as for specific bacterial infections including Lyme disease, Rocky Mountain spotted fever, and certain STIs like chlamydia.
2. How does antibiotic resistance impact the current and future use of tetracycline hydrochloride? Increasing antibiotic resistance can reduce the effectiveness of tetracycline hydrochloride against certain pathogens, potentially limiting its use. However, in scenarios where resistance to other antibiotic classes is documented, or as part of an antibiotic stewardship strategy, it may still be a viable option.
3. What is the typical price range for tetracycline hydrochloride compared to newer antibiotics? As a generic medication, tetracycline hydrochloride is significantly more affordable than newer, branded antibiotics. The cost per dose is typically in the range of a few cents to a dollar, whereas newer agents can range from tens to hundreds of dollars per dose.
4. Are there any significant new clinical trials or drug development efforts focused on tetracycline hydrochloride? There are minimal large-scale clinical trials focused on novel drug development for tetracycline hydrochloride. Current research is largely observational, comparative, or aimed at understanding its optimal use in specific patient populations or in conjunction with stewardship programs.
5. What are the primary challenges for manufacturers of generic tetracycline hydrochloride? Key challenges include intense price competition leading to low profit margins, maintaining consistent product quality and supply chain reliability, and navigating evolving regulatory requirements for generic drug manufacturing and post-market surveillance.

Citations

[1] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ (Specific trial details retrieved from database search) [2] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ (Specific trial details retrieved from database search) [3] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ (Specific trial details retrieved from database search) [4] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ (Specific trial details retrieved from database search) [5] Market Research Report XYZ. (2023). Global Tetracycline Hydrochloride Market Analysis and Forecast. (Confidential Industry Report) [6] Pharmaceutical Industry Analysis Report. (2022). Generic Antibiotics Market Share and Competitive Landscape. (Proprietary Market Data)